Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Atossa Therapeutics Inc. | Z-Endoxifen - (Karisma) | Mammographic breast density (MBD), breast cancer | Phase 2 | Data Released | Oral | Oncology |
| Atossa Therapeutics Inc. | Endoxifen | Breast cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Atossa Therapeutics Inc. | (Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE) | Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer | Phase 2 | Data Released | Oral | Oncology |
| Atossa Therapeutics Inc. | (Z)-Endoxifen - (I-SPY 2) | Locally advanced breast cancer | Phase 2 | Data Released | oral | Oncology |
| Atossa Therapeutics Inc. | (Z)-Endoxifen - (RECAST DCIS) | Ductal Carcinoma In Situ (DCIS) | Phase 2 | Enrollment Initiation | Oral | Oncology |
| Atossa Therapeutics Inc. | Endoxifen | Mammographic breast density (MBD) | Phase 2 | Trial Discontinued | Oral | Imaging/Radiopharmaceutical |
| Atossa Therapeutics Inc. | (Z)-endoxifen - (KARISMA-Endoxifen) | Breast cancer | Phase 2 | Data Released | Oral | Oncology |
| aTyr Pharma Inc. | Efzofitimod (ATYR1923) | COVID-19 | Phase 2 | Trial Completed | Intravenous | COVID-19 |
